24 results
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
13 May 24
TScan Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
7:15am
purposes.
The Company announced two upcoming poster presentations at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting being held May … medical meetings:
oAmerican Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting
oAmerican Association for Cancer Research (AACR) Annual Meeting
8-K
EX-99.2
TCRX
Tscan Therapeutics Inc
16 Apr 24
TScan Therapeutics Provides Clinical Pipeline Update and Highlights Near-Term Priorities
4:16pm
60 40 40 25 25 10 20 20 ? 0 0 0 HPV16 MAGE-C2 MAGE-A4 PRAME MAGE-A1 HPV16 MAGE-C2 MAGE-A4 PRAME MAGE-A1 Source: American Cancer Society 35
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
6 Mar 24
TScan Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
7:15am
: Transplantation & Cellular Therapy Meetings of the American Society for Transplantation and Cellular Therapy (ASTCT®) and the Center for International Blood
8-K
EX-99.1
TCRX
Tscan Therapeutics Inc
11 Dec 23
Regulation FD Disclosure
8:00am
Exhibit 99.1
TScan Therapeutics Presents Initial Phase 1 Clinical Results on TSC-100 and TSC-101 at the 65th American Society of Hematology Annual … a poster presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition. The poster highlights initial data from the Phase 1
8-K
dkibth7elm909mlnlryq
11 Dec 23
Regulation FD Disclosure
8:00am
8-K
EX-99.1
3c7qof5wmg n4
9 Nov 23
TScan Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
7:15am
8-K
EX-99.1
u81jo hsd
10 Aug 23
TScan Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
7:15am
424B5
bnyx9f1qr mam48d4
26 May 23
Prospectus supplement for primary offering
8:12pm
424B5
nskbf oth7
25 May 23
Prospectus supplement for primary offering
4:59pm
8-K
EX-99.1
8xmna65ztvl 7xj2fgj
17 May 23
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
8:15am
8-K
ck3d 1wq6
17 May 23
Poster highlights Phase 1 results following treatment with TSC-100 and TSC-101 after hematopoietic cell transplantation
8:15am
8-K
EX-99.1
xdw6kl4 2yz3
10 May 23
TScan Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:16am
8-K
EX-99.1
on26n4ep78ibwe7p9vs
9 Nov 22
TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business Update
7:06am
8-K
EX-99.1
mhf05ob
10 Aug 22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent Progress
12:00am
8-K
5yae tclh8
7 Jul 22
Departure of Directors or Certain Officers
7:11am
8-K
EX-99.1
p2edx
9 May 22
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated Milestones
7:08am
10-K
g8oqr
9 Mar 22
Annual report
7:30am